| Literature DB >> 29415196 |
Lanxiao Shen1, Shan Chen2, Xiaoyang Zhu3, Ce Han1, Xiaomin Zheng1, Zhenxiang Deng1, Yongqiang Zhou1, Changfei Gong1, Congying Xie1, Xiance Jin1.
Abstract
A multidimensional exploratory statistical method, canonical correlation analysis (CCA), was applied to evaluate the impact of complexity parameters on the plan quality and deliverability of volumetric-modulated arc therapy (VMAT) and to determine parameters in the generation of an ideal VMAT plan. Canonical correlations among complexity, quality and deliverability parameters of VMAT, as well as the contribution weights of different parameters were investigated with 71 two-arc VMAT nasopharyngeal cancer (NPC) patients, and further verified with 28 one-arc VMAT prostate cancer patients. The average MU and MU per control point (MU/CP) for two-arc VMAT plans were 702.6 ± 55.7 and 3.9 ± 0.3 versus 504.6 ± 99.2 and 5.6 ± 1.1 for one-arc VMAT plans, respectively. The individual volume-based 3D gamma passing rates of clinical target volume (γCTV) and planning target volume (γPTV) for NPC and prostate cancer patients were 85.7% ± 9.0% vs 92.6% ± 7.8%, and 88.0% ± 7.6% vs 91.2% ± 7.7%, respectively. Plan complexity parameters of NPC patients were correlated with plan quality (P = 0.047) and individual volume-based 3D gamma indices γ(IV) (P = 0.01), in which, MU/CP and segment area (SA) per control point (SA/CP) were weighted highly in correlation with γ(IV) , and SA/CP, percentage of CPs with SA < 5 × 5 cm2 (%SA < 5 × 5 cm2) and PTV volume were weighted highly in correlation with plan quality with coefficients of 0.98, 0.68 and -0.99, respectively. Further verification with one-arc VMAT plans demonstrated similar results. In conclusion, MU, SA-related parameters and PTV volume were found to have strong effects on the plan quality and deliverability.Entities:
Mesh:
Year: 2018 PMID: 29415196 PMCID: PMC5950931 DOI: 10.1093/jrr/rrx100
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.The flowchart for the overall study design.
Descrtiptive statistics of plan complexity, plan quality and deliverability parameters for nasophageal cancer and prostate cancer patients
| NPC | Prostate | ||
|---|---|---|---|
| Plan complexity | |||
| MU/CP | 3.9 ± 0.3 | 5.6 ± 1.1 | <0.001 |
| %MU/CP < 3 | 0.5 ± 0.05 | 0.3 ± 0.1 | <0.001 |
| SA(cm2)/CP | 70.1 ± 8.3 | 46.0 ± 21.8 | <0.001 |
| %SA < 5 × 5 cm2 | 66.3 ± 9.4 | 38.2 ± 20.0 | <0.001 |
| MCSv/Beam(Arc) | 0.6 ± 0.09 | 0.50 ± 0.09 | <0.001 |
| LT (mm/Arc) | 571.0 ± 27.1 | 0.5 ± 0.09 | <0.001 |
| PTV volume | 854.6 ± 168.2 | 325.5 ± 210.1 | <0.001 |
| MU | 702.6 ± 55.7 | 504.6 ± 99.2 | <0.001 |
| Plan quality | |||
| GTV | 95.4 ± 12.4 | 99. 6 ± 0.6 | 0.06 |
| PTV | 93.7 ± 3.5 | 95.5 ± 3.53 | 0.03 |
| GTV | 0.1 ± 0.03 | 0.07 ± 0.03 | <0.001 |
| PTV | 0.3 ± 0.08 | 0.1 ± 0.04 | <0.001 |
| | 0.9 ± 0.06 | 0.9 ± 0.06 | 0.64 |
| | 0.8 ± 0.05 | 0.8 ± 0.05 | 0.41 |
| Deliverability | |||
| 2D gamma passing rate (%) | |||
| 4%/4 mm | 99.2 ± 1.6 | 99.6 ± 0.4 | 0.04 |
| 3%/3 mm | 97.1 ± 1.3 | 97.9 ± 1.1 | 0.001 |
| 2%/2 mm | 87.6 ± 3.4 | 89.1 ± 3.6 | 0.05 |
| 3D gamma passing rate (%) | |||
| 4%/4 mm | 98.7 ± 0.9 | 99.6 ± 0.3 | <0.001 |
| 3%/3 mm | 96.0 ± 2.2 | 98.4 ± 0.9 | <0.001 |
| 2%/2 mm | 90.0 ± 4.3 | 93.7 ± 1.8 | <0.001 |
%MU/CP < 3 = the proportion of MU/CP less than 3, %SA < 5×5 cm2 = the proportion of SA less than 5 × 5 cm2, GTVV95% = the percent volume of the GTV covered by the 95% prescription isodose line, PTVV95% = the percent volume of the PTV covered by the 95% prescription isodose line, GTVHI = the HI of the GTV, PTVHI = the HI of the PTV.
Fig. 2.Canonical correlation analysis results for nasopharyngeal cancer patients, the x and y axes were canonical variates for (a) plan complexity vs quality; (b) plan complexity vs deliverability (2D/3D gamma indices); (c) plan complexity vs deliverability (individual volume-based gamma indices); (d) plan quality vs deliverability (2D/3D gamma indices); (e, f) plan quality vs deliverability (individual volume-based gamma indices).
The standard conanical coefficients for canonical variates among these three variable sets for NPC patients
| Complexity vs. quality | Complexity vs γ(2D/3D) | Plan quality vs.γ(2D/3D) | Complexity vs γ(IV) | Plan quality vs γ(IV) | |||
|---|---|---|---|---|---|---|---|
| Canonical variate 1 | Canonical variate 1 | Canonical variate 1 | Canonical variate 1 (γ(IV)) | Canonical variate 1 (γ(IV)) | Canonical variate 2 (γ(IV)) | ||
| Complexity parameter | |||||||
| MU/CP | −0.16 | −0.81 | −0.63 | ||||
| %MU/CP < 3 | −0.48 | −0.53 | −0.43 | ||||
| SA(cm2)/CP | 0.98 | 0.62 | −0.72 | ||||
| %SA < 5 × 5 cm2 | 0.68 | 0.47 | 0.03 | ||||
| MCSv/Beam(Arc) | −0.14 | −0.77 | 0.21 | ||||
| LT (mm/Arc) | 0.16 | 0.21 | −0.37 | ||||
| PTV volume | −0.99 | 0.34 | 0.04 | ||||
| Plan quality | |||||||
| GTV | 0.24 | −0.57 | −0.20 | 0.28 | |||
| PTV | 0.40 | −0.65 | −0.40 | 0.82 | |||
| GTV | 1.36 | −2.91 | 5.67 | 2.34 | |||
| PTV | −1.18 | −0.091 | 0.05 | −0.09 | |||
| | 2.98 | −5.73 | 9.93 | 4.27 | |||
| | −3.01 | 5.32 | −9.6 | −4.01 | |||
| Brainstem | 0.16 | −0.02 | 0.14 | −0.21 | |||
| Cord | −0.05 | −0.10 | −0.09 | −0.19 | |||
| Right parotid | −0.46 | −0.02 | −0.27 | −0.06 | |||
| Right parotid | 0.37 | 0.27 | 0.24 | 0.01 | |||
| Left parotid Dmean | 0.73 | 0.12 | −0.15 | 0.04 | |||
| Left parotid | −0.30 | −0.14 | 0.47 | −0.01 | |||
| Deliverability (2D/3D gamma indices) | Individual volume-based 3D gamma indices | ||||||
| 2D 4%/4 mm | −0.15 | −0.18 | −0.07 | 0.06 | 0.32 | γcord | |
| 2D 3%/3 mm | 1.04 | 0.093 | 0.13 | 0.80 | 0.70 | γbrainstem | |
| 2D 2%/2 mm | −0.61 | 0.097 | −0.42 | 0.12 | −0.30 | γleft parotid | |
| 3D 4%/4 mm | 3.32 | −2.51 | −0.24 | −0.47 | 0.09 | γright parotid | |
| 3D 3%/3 mm | −5.92 | 1.65 | 0.37 | −0.63 | 0.73 | γGTV | |
| 3D 2%/2 mm | 3.36 | 0.32 | −5.89 | −1.84 | 0.98 | γCTV | |
| 5.70 | 1.91 | −1.45 | γPTV | ||||
%MU/CP < 3 = the proportion of MU/CP less than 3, %SA < 5 × 5 cm2 = the proportion of SA less than 5 × 5 cm2, GTVV95% = the percentage volume of the GTV covered by the 95% prescription isodose line, PTVV95% = the percentage volume of the PTV covered by the 95% prescription isodose line, GTVHI = the HI of the GTV, PTVHI = the HI of the PTV.
The standard conanical coefficients for canonical variates among these three variable sets for prostate cancer patients
| Complexity vs quality | Complexity vs γ(2D/3D) | Plan quality vs γ(2D/3D) | Complexity vs γ(IV) | Plan quality vs γ(IV) | ||||
|---|---|---|---|---|---|---|---|---|
| Canonical variate 1 | Canonical variate 1 | Canonical variate 2 | Canonical variate1 | Canonical variate1 | Canonical variate 2 | Canonical variate 1 | ||
| Complexity parameter | ||||||||
| MU/CP | −0.49 | −0.15 | −1.57 | −1.69 | 0.53 | |||
| %MU/CP < 3 | −0.02 | 0.28 | −0.68 | −0.46 | 0.23 | |||
| SA(cm2)/CP | 0.34 | −1.14 | −2.85 | 1.63 | 2.04 | |||
| %SA < 5 × 5 cm2 | 0.18 | 0.19 | −0.85 | 0.87 | 0.66 | |||
| MCSv/Beam(Arc) | 0.26 | 0.66 | 0.17 | −0.44 | −0.13 | |||
| LT (mm/Arc) | −0.28 | 0.68 | −0.79 | 0.98 | 1.30 | |||
| PTV volume | −0.006 | 0.39 | 1.38 | −0.99 | −1.39 | |||
| Plan quality | ||||||||
| GTV | −0.51 | −0.77 | −0.26 | |||||
| PTV | 0.42 | −0.1 | −0.44 | |||||
| GTV | 3.70 | −4.33 | −8.08 | |||||
| PTV | 0.42 | −0.54 | −0.59 | |||||
| | 6.28 | −6.05 | −12.86 | |||||
| | −5.81 | 5.54 | 11.96 | |||||
| Rectum | 0.31 | 0.09 | −0.64 | |||||
| Rectum | −0.50 | 0.1 | 0.86 | |||||
| Bladder | −0.44 | 0.07 | 0.48 | |||||
| Bladder | 0.42 | 0.03 | −0.66 | |||||
| Rfemoral | 0.83 | −0.61 | −0.38 | |||||
| Lfemoral | −3.20 | −0.04 | 0.81 | |||||
| Deliverability (2D/3D gamma indices) | Individual volume-based 3D gamma indices γ(IV) | |||||||
| 2D 4%/4 mm | 0.86 | 0.81 | 0.69 | 0.009 | −0.95 | −0.49 | γGTV | |
| 2D 3%/3 mm | −0.80 | −0.86 | −0.07 | 0.37 | −0.56 | −1.16 | γCTV | |
| 2D 2%/2 mm | −0.24 | −0.11 | −1.14 | 0.35 | 0.58 | 0.84 | γPTV | |
| 3D 4%/4 mm | −0.48 | −0.30 | 0.03 | 0.55 | 0.18 | −0.52 | γRectum | |
| 3D 3%/3 mm | 0.11 | 1.51 | 0.26 | 0.69 | 0.11 | −0.10 | γlfemoral | |
| 3D 2%/2 mm | −0.25 | −0.47 | 0.56 | 0.19 | 0.11 | 0.32 | γr femoral | |
| −0.82 | 0.18 | 0.39 | γbladder | |||||
%MU/CP < 3 = the proportion of MU/CP less than 3, %SA < 5 × 5 cm2 = the proportion of SA less than 5 × 5 cm2, GTVV95% = the percentage volume of the GTV covered by the the 95% prescription isodose line, PTVV95% = the percentage volume of the PTV covered by the 95% prescription isodose line, GTVHI = the HI of the GTV, PTVHI = the HI of the PTV, lfemoral = left femoral head, rfemoral = right femoral head.